MATN3 and neoplasm: hOA-DN30 showed a therapeutic effect, inhibiting GTL-16 tumor growth with a dose-response behavior (29%, 83%, and 92% inhibition at 3.3, 10, and 60 mg/kg three times a week, respectively; Fig. 4A).